As American drug companies adjust to an increasingly competitive global marketplace, Katherine A. Helm, a technical advisor to the Fish & Neave IP Group of Ropes & Gray, argues that U.S. patent jurisprudence should embrace – rather than fight – the phenomenon of globalization. In her article, published in the Fordham Intellectual Property, Media & Entertainment Law Journal, Helm examines the various forces faced by drug companies and concludes that the U.S. patent system should allow American pharmaceutical companies to leverage their intangible assets while permitting scientific innovation to advance in the U.S. and throughout the world. To read Helm's article, please click "Download PDF."
